ENDRA Life Sciences Inc.

NasdaqCM:NDRA Stock Report

Market Cap: US$6.3m

ENDRA Life Sciences Balance Sheet Health

Financial Health criteria checks 4/6

ENDRA Life Sciences has a total shareholder equity of $1.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.4M and $1.7M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$356.46k
EquityUS$1.79m
Total liabilitiesUS$1.65m
Total assetsUS$3.44m

Recent financial health updates

Recent updates

Seeking Alpha • Sep 29

ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks

ENDRA Life Sciences (NASDAQ:NDRA) on Thursday said it would submit a De Novo request to the U.S. FDA in the coming weeks for its TAEUS liver disease monitoring system. The FDA's De Novo process gives companies a pathway to classify medical devices which are not already based on a legally marketed device and for which general controls provide reasonable assurance of safety and effectiveness. "I'm pleased to announce that preparation of the De Novo documentation by the end of the third quarter is substantially complete," NDRA CEO Francois Michelon said in a statement. The company's TAEUS system characterizes fatty liver tissue, thus allowing one to monitor for non-alcoholic fatty liver disease. NDRA said the system was already approved for sale in countries that recognize the CE Mark, including those in the European Union. ENDRA (NDRA) stock earlier closed +4.2% at $0.32.
Seeking Alpha • Aug 24

ENDRA Life Sciences receives European patent for TAEUS system

ENDRA Life Sciences (NASDAQ:NDRA) said on Wednesday the European Patent Office had issued Patent for its TAEUS system to calculate fat concentration in the human body with multiple thermoacoustic measurements. The company has the same patent protection in the U.S. and China. The patent is titled "System for Estimating Fractional Fat Content of an Object." The company's Thermo-Acoustic Enhanced UltraSound (TAEUS) combines radio frequency and ultrasound waves to measure fat in the liver. "Our portfolio currently features 54 patents issued globally, including eight issued in Europe," the company said. (NDRA) is trading 5% higher premarket.
Seeking Alpha • Aug 12

Endra Life Sciences Q2 2022 Earnings Preview

Endra Life Sciences (NASDAQ:NDRA) is scheduled to announce Q2 earnings results on Monday, August 15th, after market close. The consensus EPS Estimate is -$0.06 Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.
Analysis Article • Aug 08

We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 18

We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jul 19

We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Financial Position Analysis

Short Term Liabilities: NDRA's short term assets ($536.7K) do not cover its short term liabilities ($835.4K).

Long Term Liabilities: NDRA's short term assets ($536.7K) do not cover its long term liabilities ($815.9K).

Debt to Equity History and Analysis

Debt Level: NDRA is debt free.

Reducing Debt: NDRA has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NDRA has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: NDRA is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 16:57
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ENDRA Life Sciences Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Kyle BauserColliers Securities